Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes

10 March 2020 - The terminology used to describe community participation in health technology assessment is contested and frequently confusing.  ...

Read more →

Broader types of data to be used in development of NICE guidance

4 February 2020 - An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact ...

Read more →

ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework

31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...

Read more →

Use of patient preference studies in HTA decision making: a NICE perspective

16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...

Read more →

Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations

14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...

Read more →

FDA approves drugs faster than ever but relies on weaker evidence, researchers find

14 January 2020 - The FDA has gotten faster at approving new prescription drugs over the past four decades, but ...

Read more →

Should access to life saving medicines be determined by economic evaluations?

9 January 2020 - Time is the most precious commodity all of us have.  ...

Read more →

Adding patient reported outcomes to Medicare’s oncology value-based payment model

2 January 2020 - On 1 November 2019, the Centers for Medicare & Medicaid Services Innovation Center released details of a ...

Read more →

Request for information on lamotrigine brand change

 9 December 2019 - The request, dated 15 November 2019, asked for all and any advice or information or guidance that ...

Read more →

Expanding use of multi-criteria decision analysis for health technology assessment

11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...

Read more →

The use of risk-sharing contracts in health care: theoretical and empirical assessments

3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...

Read more →

Could or should we use MCDA in the French HTA process?

3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...

Read more →

ICER opens nominations for new members of its voting panels

25 November 2019 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada

15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...

Read more →

Little consistency in evidence cited by commercial plans for specialty drug coverage

5 November 2019 - Recently published research indicates wide variation in the evidence that US commercial health plans reported reviewing ...

Read more →